Aptevo Therapeutics Reports 3Q 2024 Financial Results and Provides a Business Update
APVO 11.07.2024
About Gravity Analytica
Recent News
- 01.15.2025 - Aptevo's Peter Pavlik, PhD, Chairing Session on "Bi and Multispecific Biologics" at Cambridge Healthcare Institute's Pep Talk 2025
- 12.12.2024 - Aptevo Therapeutics Announces Exercise of Warrants for $6.2 Million Gross Proceeds
- 12.12.2024 - 100% of Patients Achieve Remission Within 30 Days in Cohort 1 of Bispecific Mipletamig Frontline AML Trial
Recent Filings
Company Achieves Milestones in Both Clinical Programs
Initiates Mipletamig Phase 1b/2 Clinical Trial, "RAINIER," in Frontline Acute Myeloid Leukemia, Informed by Positive Dose Escalation Trial Results
Presented Interim Data from ALG.APV-527 Phase 1 Trial in Multiple Solid Tumors at the
Additional Favorable Data to be Presented at the
Raises
Business HighlightsAptevo met multiple clinical milestones in the third quarter, including:
Based on positive safety, tolerability efficacy and durability data in its completed dose escalation trial, Aptevo Initiated the mipletamig Phase 1b/2 dose optimization trial, "RAINIER," as part of its ongoing program to evaluate the compound in combination with standard of care venetoclax + azacitidine in frontline patients with acute myeloid leukemia (AML). RAINIER will be conducted in two parts. First, a Phase 1b frontline AML dose optimization study followed by a Phase 2 study
Presented positive interim data from their Phase 1 trial evaluating ALG.APV-527 as monotherapy for the treatment of solid tumors likely to express the tumor antigen 5T4 at the
European Society of Medical Oncology (ESMO) Congress in September. Additional positive trial data will be presented at theSociety for Immunotherapy of Cancer conference onNovember 9 th.Highlights from the ESMO presentation include:
Clinical Activity/Efficacy:To date,nine of 15 efficacy evaluable patients (60%) have a best overall response of stable disease (SD). The longest SD duration was in a breast cancer patient who entered the study with progressive disease, achieved stable disease and remained on study for >11 months. This patient successfully transitioned to a higher dose level twice.
Safety and Tolerability:ALG.APV-527 demonstrated a well-tolerated safety profile across all dose-level cohorts dosed to date.
Evidence of biological activity:ALG.APV-527 could be measured in all patients with serum concentration of ALG.APV-527 consistent with the administered dose and preclinical predictions. Biomarker analyses confirm biological activity of ALG.APV-527
Closed two financings for total proceeds of
$5.75 million during the quarter
"Aptevo achieved significant clinical progress in both programs this quarter, marking important progress toward our mission and goals. We were thrilled to initiate the next phase of our mipletamig development program-a robust Phase 1b/2 trial for frontline AML patients, combining mipletamig with the established standard of care, venetoclax and azacitidine. This trial structure is informed by the encouraging results from our dose expansion trial, reinforcing our belief in mipletamig's transformative potential for AML patients," stated
3Q Summary Financial Results
Cash Position:Aptevo had cash and cash equivalents totaling
Research and Development Expenses:Research and development expenses decreased by
General and Administrative Expenses:General and administrative expenses decreased by
Other Income (Expense), Net:Other Income (Expense) from Continuing Operations, Netconsists of other income, net of
Net Income (Loss):Aptevo had a net loss of
ASSETS | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 7,753 | $ | 16,904 | ||||
Prepaid expenses | 1,635 | 1,473 | ||||||
Other current assets | 624 | 689 | ||||||
Total current assets | 10,012 | 19,066 | ||||||
Property and equipment, net | 614 | 895 | ||||||
Operating lease right-of-use asset | 4,520 | 4,881 | ||||||
Total assets | $ | 15,146 | $ | 24,842 | ||||
LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
Current liabilities: | ||||||||
Accounts payable and other accrued liabilities | $ | 3,532 | $ | 3,984 | ||||
Accrued compensation | 922 | 2,098 | ||||||
Other current liabilities | 1,428 | 1,142 | ||||||
Total current liabilities | 5,882 | 7,224 | ||||||
Other long-term liabilities | 14 | - | ||||||
Operating lease liability | 4,830 | 5,397 | ||||||
Total liabilities | 10,726 | 12,621 | ||||||
Stockholders' equity: | ||||||||
Preferred stock: shares issued or outstanding | - | - | ||||||
Common stock: 17,050,536 and 442,458 shares issued and outstanding at | 82 | 61 | ||||||
Additional paid-in capital | 245,603 | 235,607 | ||||||
Accumulated deficit | (241,265 | ) | (223,447 | ) | ||||
Total stockholders' equity | 4,420 | 12,221 | ||||||
Total liabilities and stockholders' equity | $ | 15,146 | $ | 24,842 | ||||
For the Three Months Ended | For the Nine Months Ended | |||||||||||||||
2024 | 2023 | 2024 | 2023 | |||||||||||||
Operating expenses: | ||||||||||||||||
Research and development | $ | (3,103 | ) | $ | (3,887 | ) | (10,498 | ) | (13,516 | ) | ||||||
General and administrative | (2,110 | ) | (2,674 | ) | (7,722 | ) | (8,978 | ) | ||||||||
Loss from operations | (5,213 | ) | (6,561 | ) | (18,220 | ) | (22,494 | ) | ||||||||
Other income: | ||||||||||||||||
Other income from continuing operations, net | 112 | 227 | 402 | 390 | ||||||||||||
Gain related to sale of non-financial asset | - | - | - | 9,650 | ||||||||||||
Net loss from continuing operations | $ | (5,101 | ) | $ | (6,334 | ) | $ | (17,818 | ) | $ | (12,454 | ) | ||||
Discontinued operations: | ||||||||||||||||
Income from discontinued operations | $ | - | $ | - | $ | - | $ | 946 | ||||||||
Net loss | $ | (5,101 | ) | $ | (6,334 | ) | $ | (17,818 | ) | $ | (11,508 | ) | ||||
Basic and diluted net loss per share from continuing operations: | ||||||||||||||||
Basic | $ | (0.48 | ) | $ | (22.16 | ) | $ | (5.01 | ) | $ | (60.84 | ) | ||||
Diluted | $ | (0.48 | ) | $ | (22.16 | ) | $ | (5.01 | ) | $ | (60.84 | ) | ||||
Basic and diluted net loss per share: | ||||||||||||||||
Basic | $ | (0.48 | ) | $ | (22.16 | ) | $ | (5.01 | ) | $ | (56.22 | ) | ||||
Diluted | $ | (0.48 | ) | $ | (22.16 | ) | $ | (5.01 | ) | $ | (56.22 | ) | ||||
Shares used in calculation: | ||||||||||||||||
Basic | 10,548,470 | 285,886 | 3,554,796 | 204,694 | ||||||||||||
Diluted | 10,548,470 | 285,886 | 3,554,796 | 204,694 | ||||||||||||
About
Safe Harbor Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, without limitation, Aptevo's expectations about the activity, efficacy, safety, tolerability and durability of its therapeutic candidates and potential use of any such candidates, including in combination with other drugs, as therapeutics for treatment of disease, its expectations regarding the effectiveness of its ADAPTIR and ADAPTIR-FLEX platforms, statements related to the progress of Aptevo's clinical programs, including statements related to anticipated clinical and regulatory milestones, whether further study of mipletamig in a Phase 1b dose optimization trial focusing on multiple doses of mipletamig in combination with venetoclax + azacitidine on a targeted patient population will continue to show clinical benefit, whether Aptevo's final trial results will vary from its earlier assessment, whether further study of ALG.APV-527 across multiple tumor types will continue to show clinical benefit, whether higher dose ranges for ALG.APV-527 will result in increased signs of clinical activity, whether biomarker analyses will continue to confirm biological activity of ALG.APV-527, the possibility and timing of future preliminary or interim data readouts for ALG.APV-527, whether Aptevo's final trial results will vary from its preliminary or interim assessments, statements related to the progress of and enthusiasm for Aptevo's clinical programs, statements related to Aptevo's cash position and balance sheet, statements related to Aptevo's ability to generate stockholder value, whether Aptevo will continue to have momentum in its business in the future, and any other statements containing the words "may," "continue to," "believes," "knows," "expects," "optimism," "potential," "designed," "promising," "plans," "will" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on Aptevo's current intentions, beliefs, and expectations regarding future events. Aptevo cannot guarantee that any forward-looking statement will be accurate. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from Aptevo's expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement.
There are several important factors that could cause Aptevo's actual results to differ materially from those indicated by such forward-looking statements, including a deterioration in Aptevo's business or prospects; further assessment of preliminary or interim data or different results from later clinical trials; adverse events and unanticipated problems, adverse developments in clinical development, including unexpected safety issues observed during a clinical trial; and changes in regulatory, social, macroeconomic and political conditions. For instance, actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the uncertainties inherent in the results of preliminary or interim data and preclinical studies being predictive of the results of later-stage clinical trials, initiation, enrollment and maintenance of patients, and the completion of clinical trials, the availability and timing of data from ongoing clinical trials, the trial design includes combination therapies that may make it difficult to accurately ascertain the benefits of mipletamig, expectations for the timing and steps required in the regulatory review process, expectations for regulatory approvals, the impact of competitive products, our ability to enter into agreements with strategic partners or raise funds on acceptable terms or at all and other matters that could affect the availability or commercial potential of Aptevo's product candidates, business or economic disruptions due to catastrophes or other events, including natural disasters or public health crises such as the coronavirus (referred to as COVID-19), geopolitical risks, including the current war between
CONTACT:
SOURCE: